Last reviewed · How we verify
OPTIVE PLUS®
OPTIVE PLUS® contains sodium hyaluronate and polyethylene glycol, which work together to lubricate and protect the ocular surface.
OPTIVE PLUS® contains sodium hyaluronate and polyethylene glycol, which work together to lubricate and protect the ocular surface. Used for Dry eye syndrome.
At a glance
| Generic name | OPTIVE PLUS® |
|---|---|
| Sponsor | Allergan |
| Drug class | ocular lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 2 |
Mechanism of action
Sodium hyaluronate is a natural component of the eye that helps retain moisture, while polyethylene glycol acts as a surfactant to spread the solution evenly over the cornea, reducing dryness and irritation.
Approved indications
- Dry eye syndrome
Common side effects
- Eye irritation
- Blurred vision
Key clinical trials
- A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease (PHASE3)
- Hyaluronic Acid-containing Artificial Tears in Post-cataract Surgery Dry Eye Disease (PHASE4)
- Clinical Outcomes Following Treatment With SYSTANE® BALANCE (NA)
- A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye (PHASE4)
- Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy (PHASE4)
- A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease (PHASE3)
- Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease (PHASE3)
- A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OPTIVE PLUS® CI brief — competitive landscape report
- OPTIVE PLUS® updates RSS · CI watch RSS
- Allergan portfolio CI